OBJECTIVE: To determine whether extending the interval between chemoradiation (CRT) and surgery, and administering additional chemotherapy during the waiting period has an impact on tumor response, CRT-related toxicity and surgical complications in patients with advanced rectal cancer. BACKGROUND: Locally advanced rectal cancer is usually treated with preoperative CRT followed by surgery approximately 6 weeks later. The Timing of Rectal Cancer Response to Chemoradiation Consortium designed a prospective, multicenter, Phase II clinical trial to investigate extending the interval between CRT and surgery, and administering additional chemotherapy during the waiting period. Here, we present preliminary results of this trial, reporting the tumor response, CRT-related toxicity and surgical complications. METHODS: Stage II and III rectal cancer patients were treated concurrently with 5-Fluorouracil (FU) and radiation for 5 to 6 weeks. Patients in study group (SG) 1 underwent total mesorectal excision (TME) 6 weeks later. Patients in SG2 with evidence of a clinical response 4 weeks after CRT received 2 cycles of modified FOLFOX-6 (mFOLFOX-6) followed by TME 3 to 5 weeks later. Tumor response, CRT-related toxicity and surgical complications were recorded. RESULTS: One hundred and forty-four patients were accrued. One hundred and thirty-six (66, SG1; 70, SG2) were evaluated for CRT-related toxicity. One hundred and twenty-seven (60, SG1; 67, SG2) were assessed for tumor response and surgical complications. A similar proportion of patients completed CRT per protocol in both SGs, but the cumulative dose of sensitizing 5-FU and radiation was higher in SG2. CRT-related toxicity was comparable between SGs. Average time from CRT-to-surgery was 6 (SG1) and 11 weeks (SG2). Pathologic complete response (pCR) was 18% (SG1) and 25% (SG2). Postoperative complications were similar between SGs. CONCLUSIONS: Intense neoadjuvant therapy consisting of CRT followed by additional chemotherapy (mFOLFOX-6), and delaying surgery may result in a modest increase in pCR rate without increasing complications in patients undergoing TME for locally advanced rectal cancer.
OBJECTIVE: To determine whether extending the interval between chemoradiation (CRT) and surgery, and administering additional chemotherapy during the waiting period has an impact on tumor response, CRT-related toxicity and surgical complications in patients with advanced rectal cancer. BACKGROUND: Locally advanced rectal cancer is usually treated with preoperative CRT followed by surgery approximately 6 weeks later. The Timing of Rectal Cancer Response to Chemoradiation Consortium designed a prospective, multicenter, Phase II clinical trial to investigate extending the interval between CRT and surgery, and administering additional chemotherapy during the waiting period. Here, we present preliminary results of this trial, reporting the tumor response, CRT-related toxicity and surgical complications. METHODS: Stage II and III rectal cancerpatients were treated concurrently with 5-Fluorouracil (FU) and radiation for 5 to 6 weeks. Patients in study group (SG) 1 underwent total mesorectal excision (TME) 6 weeks later. Patients in SG2 with evidence of a clinical response 4 weeks after CRT received 2 cycles of modified FOLFOX-6 (mFOLFOX-6) followed by TME 3 to 5 weeks later. Tumor response, CRT-related toxicity and surgical complications were recorded. RESULTS: One hundred and forty-four patients were accrued. One hundred and thirty-six (66, SG1; 70, SG2) were evaluated for CRT-related toxicity. One hundred and twenty-seven (60, SG1; 67, SG2) were assessed for tumor response and surgical complications. A similar proportion of patients completed CRT per protocol in both SGs, but the cumulative dose of sensitizing 5-FU and radiation was higher in SG2. CRT-related toxicity was comparable between SGs. Average time from CRT-to-surgery was 6 (SG1) and 11 weeks (SG2). Pathologic complete response (pCR) was 18% (SG1) and 25% (SG2). Postoperative complications were similar between SGs. CONCLUSIONS: Intense neoadjuvant therapy consisting of CRT followed by additional chemotherapy (mFOLFOX-6), and delaying surgery may result in a modest increase in pCR rate without increasing complications in patients undergoing TME for locally advanced rectal cancer.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: S Supiot; J Bennouna; E Rio; G Meurette; E Bardet; B Buecher; F Dravet; J-C Le Neel; J-Y Douillard; M-A Mahé; P-A Lehur Journal: Colorectal Dis Date: 2006-06 Impact factor: 3.788
Authors: David E Stein; Najjia N Mahmoud; Pramila Rani Anné; Deborah G Rose; Gerald A Isenberg; Scott D Goldstein; Edith Mitchell; Robert D Fry Journal: Dis Colon Rectum Date: 2003-04 Impact factor: 4.585
Authors: C M Dolinsky; N N Mahmoud; R Mick; W Sun; R W Whittington; L J Solin; D G Haller; B J Giantonio; P J O'Dwyer; E F Rosato; R D Fry; J M Metz Journal: J Surg Oncol Date: 2007-09-01 Impact factor: 3.454
Authors: Raphael Pelossof; Oliver S Chow; Lauren Fairchild; J Joshua Smith; Manu Setty; Chin-Tung Chen; Zhenbin Chen; Fumiko Egawa; Karin Avila; Christina S Leslie; Julio Garcia-Aguilar Journal: Genes Chromosomes Cancer Date: 2016-04 Impact factor: 5.006
Authors: Eric Sorenson; Fernando Lambreton; Jian Q Yu; Tianyu Li; Crystal S Denlinger; Joshua E Meyer; Elin R Sigurdson; Jeffrey M Farma Journal: J Surg Res Date: 2019-06-21 Impact factor: 2.192
Authors: Annefleur E M Berkel; Dankert P Woutersen; Job van der Palen; Joost M Klaase Journal: J Gastrointest Surg Date: 2014-06-18 Impact factor: 3.452
Authors: Tara E Seery; Argyrios Ziogas; Bruce S Lin; Chuan-Ju G Pan; Michael J Stamos; Jason A Zell Journal: J Gastrointest Surg Date: 2012-12-14 Impact factor: 3.452